Fig. 5.
Fig. 5. Treatment of SCID mice bearing human Hodgkin’s lymphoma xenografts with bispecific antibodies. The mice were treated on day 0 by intravenous injection with 200 μL PBS (x); 1 × 107human peripheral blood lymphocytes (PBL) in 200 μL PBS (□); a mixture of 100 μg parental MoAb HRS-3 and A9 together with human PBL (◊); 100 μg purified anti-CD16/anti-CD30 diabody with human PBL (◍) or without human PBL (○); 100 μg purified biMoAb HRS-3/A9 together with human PBL (▴). Tumor diameters were recorded twice a week and tumor volume was calculated as follows: volume = d2 × D × π/6 with d as the smaller and D as the larger tumor diameter.

Treatment of SCID mice bearing human Hodgkin’s lymphoma xenografts with bispecific antibodies. The mice were treated on day 0 by intravenous injection with 200 μL PBS (x); 1 × 107human peripheral blood lymphocytes (PBL) in 200 μL PBS (□); a mixture of 100 μg parental MoAb HRS-3 and A9 together with human PBL (◊); 100 μg purified anti-CD16/anti-CD30 diabody with human PBL (◍) or without human PBL (○); 100 μg purified biMoAb HRS-3/A9 together with human PBL (▴). Tumor diameters were recorded twice a week and tumor volume was calculated as follows: volume = d2 × D × π/6 with d as the smaller and D as the larger tumor diameter.

Close Modal

or Create an Account

Close Modal
Close Modal